Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
DUCK (DuckChain) fluctuates by 69.4% in 24 hours: profit-taking dominates the pullback after surge in trading volume

DUCK (DuckChain) fluctuates by 69.4% in 24 hours: profit-taking dominates the pullback after surge in trading volume

Bitget PulseBitget Pulse2026/04/01 16:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, DUCK's price surged from a low of $0.000500 to a high of $0.000847, with the current quote at $0.000503, marking an overall amplitude of 69.4%. The 24-hour trading volume expanded significantly to approximately $2.01 million, up 38.5% from the previous day, with clear signs of net capital outflow.

Brief Analysis of Unusual Movement

• Surge in Trading Volume: The 24-hour trading amount rose to $1.72–3.06 million, driving a short-term price spike, but there was no clear news or announcement catalyst.

• Profit-taking Dominates: The price quickly pulled back from the highs of $0.001029/$0.001078 to the $0.0005 range, mainly due to profit-taking and capitulation selling by traders, with no evidence of whale large transfers or abnormal on-chain activity recorded.

Market Opinion and Outlook

The mainstream market sentiment is cautious and negative, viewing this as capitulation of selling in a continued downtrend. The 24-hour decline reached 47.46%, with limited discussion in the community, and most see the price and volume fluctuation as happening without catalysts. Analysts highlight high short-term risks and warn of further retracement, but some predict a rebound to $0.001426 by the end of 2026.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23